This work was conducted to protect cardiomyocytes from dying during myocardial infarction. Currently, it is only possible to induce angiogenesis as well as myogenesis of the heart by stem cell therapy, leading to a partial regeneration of the heart muscle. Therefore, the Edelweiss agent, 5'-Methoxyleoligin (LAG2), which was previously tested in an in vivo myocardial infarction model may be responsible for the improved function of the heart. Accordingly, LAG2 was examined in an in vitro cardiomyocyte model with HL-1 cells to see whether the drug may protect the cells and if so, to define the best treatment regime. LAG2 was tested in four different incubation schemes, in which cells were exposed to hypoxic and normoxic conditions. The analyses used were AnnexinV/PI FACS, XTT proliferation assay and Western blot analysis for the detection of vascular endothelial growth factor (VEGF). During the incubation scheme, in which the HL-1 cells were incubated with LAG2 in the reperfusion for four hours, LAG2 incubation (50 µM) achieved a significant increase in living cells in comparison to controls (DMSO) in the AnnexinV/PI FACS, but in the XTT proliferation assay LAG2 did not cause increased cell proliferation. In Western blot analysis of this scheme, the protein VEGF has been detected. Increased VEGF expression is probably caused by LAG2 under hypoxia. Based on the results, it can be shown that LAG2 can protect the cardiomyocytes from cell death.